{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:04Z","timestamp":1790790844632,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Biofrontera Pharma GmbH, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,7]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Non\u2010melanoma skin cancer (NMSC<\/jats:styled-content>) and actinic keratosis (AK<\/jats:styled-content>) are very common among fair\u2010skinned individuals. A disease continuum fromAK<\/jats:styled-content>to squamous cell carcinoma (SCC<\/jats:styled-content>) has been frequently postulated.AK<\/jats:styled-content>andNMSC<\/jats:styled-content>may influence quality of life (QL<\/jats:styled-content>) of patients, and it can be suspected that disease progression entails aQL<\/jats:styled-content>reduction. The purpose of this study was to documentQL<\/jats:styled-content>in patients withNMSC<\/jats:styled-content>andAK<\/jats:styled-content>using the health\u2010outcome questionnaireEQ<\/jats:styled-content>\u20105D\u20105L.<\/jats:p><\/jats:sec>Methods<\/jats:title>The study was designed as a non\u2010interventional, prospective, cross\u2010sectional study. Patients withAK<\/jats:styled-content>,SCC<\/jats:styled-content>, basal cell carcinoma (BCC<\/jats:styled-content>) or multiple diagnoses were enrolled in this study in 29 dermatological centres across Germany. Patients were asked to complete theEQ<\/jats:styled-content>\u20105D\u20105L (compromisingEQ<\/jats:styled-content>Index andEQ VAS<\/jats:styled-content>), and the dermatologists provided diagnosis, disease history and treatment data.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 1184 patients were enrolled and diagnosed as follows: 73%AK<\/jats:styled-content>, 49%BCC<\/jats:styled-content>and 17%SCC<\/jats:styled-content>. 66% had a single diagnosis, 28% two different diagnoses and 6% three different diagnoses.QL<\/jats:styled-content>was strongly associated with patients\u2019 diagnosis. Patients with a singleAK<\/jats:styled-content>diagnosis had significantly higher meanEQ VAS<\/jats:styled-content>(78) than patients withBCC<\/jats:styled-content>(74),SCC<\/jats:styled-content>(72), andBCC<\/jats:styled-content>plusSCC<\/jats:styled-content>(69),P<\/jats:italic>< 0.050. When the effects of disease progression were calculated, patients withAK<\/jats:styled-content>plusSCC<\/jats:styled-content>reported significantly less meanEQ VAS<\/jats:styled-content>(71) than patients with a singleAK<\/jats:styled-content>diagnosis (78),P<\/jats:italic>< 0.011.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>While rarely being imminently life\u2010threatening,NMSC<\/jats:styled-content>andAK<\/jats:styled-content>have an impact onQL<\/jats:styled-content>as quantified by theEQ<\/jats:styled-content>\u20105D\u20105L. This impact is associated with diagnosis (AK<\/jats:styled-content>vs.NMSC<\/jats:styled-content>) and clinical progression (AK<\/jats:styled-content>vs.AK<\/jats:styled-content>plusSCC<\/jats:styled-content>). Both lead to a clear decline inQL<\/jats:styled-content>. This shows that disease progression is perceived and judged as detrimental by patients and thatAK<\/jats:styled-content>andNMSC<\/jats:styled-content>should be diligently treated to preserve and restoreQL<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14703","type":"journal-article","created":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T04:06:42Z","timestamp":1510978002000},"page":"1138-1146","source":"Crossref","is-referenced-by-count":31,"title":["Patient\u2010reported health outcomes in patients with non\u2010melanoma skin cancer and actinic keratosis: results from a large\u2010scale observational study analysing effects of diagnoses and disease progression"],"prefix":"10.1111","volume":"32","author":[{"given":"W.G.","family":"Philipp\u2010Dormston","sequence":"first","affiliation":[{"name":"Hautzentrum K\u00f6ln (Cologne Dermatology) K\u00f6ln Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Centre for Clinical Studies University Hospital Regensburg Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Novak","sequence":"additional","affiliation":[{"name":"Biofrontera Pharma GmbH Leverkusen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Str\u00f6mer","sequence":"additional","affiliation":[{"name":"Professional Association of German Dermatologists (BVDD) M\u00f6nchengladbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Termeer","sequence":"additional","affiliation":[{"name":"Hautarztpraxis am L\u00f6wenmarkt Dematology Practice Stuttgart Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Hammann","sequence":"additional","affiliation":[{"name":"Hautarztpraxis Dr. med. Urte Hammann Dermatology Practice Stade Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Glutsch","sequence":"additional","affiliation":[{"name":"Hautarztpraxis Dr. med. J. W. Glutsch Dermatology Practice Karlsruhe Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kr\u00e4hn\u2010Senftleben","sequence":"additional","affiliation":[{"name":"Hautzentrum Donau Alb Dermatology Practice Blaubeuren Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"L\u00fcbbert","sequence":"additional","affiliation":[{"name":"Biofrontera Pharma GmbH Leverkusen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Koller","sequence":"additional","affiliation":[{"name":"Centre for Clinical Studies University Hospital Regensburg Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Szeimies","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Vest Clinic Recklinghausen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NMSC\u2010QoL Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10830.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.304"},{"key":"e_1_2_6_4_1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK AWMF).S3\u2010Leitlinie Pr\u00e4vention von Hautkrebs: Kurzversion 1.1 [AWMF\u2010Registernummer: 032\/0520L]2014. Available at:http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/032-052OLk_Pravention_von_Hautkrebs_2014-04.pdf[last accessed 20 July 2017]."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.9.1216"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08267.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103339"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12420"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103342"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08544.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03541.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.7.837"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12205"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13180"},{"key":"e_1_2_6_16_1","first-page":"241","article-title":"What is the role of field\u2010directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents","volume":"89","author":"Berman B","year":"2012","journal-title":"Cutis"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00434740"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30169.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07547_suppl.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.11.1386"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700740"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLG.0b013e31802e2d88"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12036"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366530"},{"key":"e_1_2_6_25_1","first-page":"25","article-title":"Differences in disease\u2010specific quality of life in patients with actinic keratosis in Australia and Denmark","volume":"24","author":"Miller IM","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.03.003"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12310"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12406"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0679-8"},{"key":"e_1_2_6_31_1","unstructured":"EuroQol.EQ\u20105D 2017. Available at:https:\/\/euroqol.org\/[last accessed 20 July 2017]."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.01.003"},{"key":"e_1_2_6_33_1","unstructured":"vanReenenM JanssenB.EQ\u20105D\u20105L User Guide: EuroQol Research Foundation;2015.https:\/\/euroqol.org\/wp-content\/uploads\/2016\/09\/EQ-5D-5L_UserGuide_2015.pdf. [last accessed 20 July 2017]."},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-71"},{"key":"e_1_2_6_35_1","unstructured":"Development OfEC\u2010oa.Classifying educational programmes: manual for ISCED\u201097 implementation in OECD countries1999. Available at:http:\/\/www.oecd.org\/education\/skills-beyond-school\/1962350.pdf. [last accessed 20 July 2017]"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0537-0"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1997.10473623"},{"key":"e_1_2_6_38_1","first-page":"249","article-title":"A review on quality of life in keratinocyte carcinoma patients","volume":"148","author":"Waalboer\u2010Spuij R","year":"2013","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_6_39_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ddg.12690","article-title":"Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010","volume":"13","author":"Rudolph C","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2139"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12848"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14151"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2008.07034"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2009.01291.x"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538670-000000000-00000"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0211-7"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X03259817"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09112.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0295-4"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-003-0182-5"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0498-2"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1_4"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph13030343"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-006-9156-2"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-113188"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T19:32:18Z","timestamp":1719603138000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/jdv.14703"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14703","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]}}}